Discover and read the best of Twitter Threads about #Aspergillosis

Most recents (5)

Our newest study of #emergingfungalinfections

Covid-assoc #aspergillosis reportedly occurs in <1/3 ICU patients, but dx is rarely biopsy confirmed

By reviewing autopsy studies, we found proven invasive mould infections occur in 2% of decedents w covid

sciencedirect.com/science/articl…
Major caveat is that most autopsies included were from first wave, pre-#RECOVERYtrial and use of steroids and other immunomodulation likely increase risk of #CAPA.

NB to know your local epi, which may differ; for eg of centers reporting >>> rates, see link.springer.com/article/10.100… &👇
Big congratulations to Dr Brittany Kula (@ScrofKula), ID fellow extraordinaire @UofA_ID and soon @UAlberta_ICU fellow, for doing a wonderful job leading this study. Brittany is pictured in the first tweet, and here is her cat Gladys
Read 4 tweets
@GenScript @iGEM Our iGEM team is working to make an #impact by reducing fungal contamination and sporulation in diverse settings like commercial residences, hospitals, and agriculture. 🧬 @GenScript @iGEM (1/5)
@GenScript @iGEM Moulds affect human health. #Aspergillosis infection severely affects the respiratory system in humans. Mucormycosis is a severe invasive fungal infection mainly affecting immunocompromised patients. 🔬 (2/5)
@GenScript @iGEM Development of cavitary pulmonary mucormycosis is increasingly reported in SARS-CoV2 patients. Glucocorticoids used for the treatment of Covid lead to secondary fungal infection. Our solution will potentially degrade the infection source & prevent further complications. 🧫 (3/5)
Read 6 tweets
Finally got to analyze & put my thoughts together on the recent #posaconazole vs. #voriconazole phase 3 trial for invasive #aspergillosis published in .@TheLancet a few weeks ago.
Best is to put the major trials of the 3 #VIP triazoles done over the last 20 years in perspective!
Here is the table with key points of trial design of the #TresAmigos trials, interesting features:

#Vori-Ampho was open label, but with blinded adjudication, including to adverse effects.

All where non-inferiority trials, #vori-amphoB had a clause for claiming superiority.
Read 20 tweets
Hey #MedTwitter!!
This morning at our VA we had Chief @photon_ick give us a case of #ChronicSOB, where it turned out that the patient had #ABPA (#allergic bronchopulmonary #aspergillosis). It's a diagnosis we don't see too often, but one you'll definitely encounter here!! 🗝️👇
This is an #allergic condition, with 2 main predisposing conditions: #asthma & #cysticfibrosis
It can be more rarely seen in other lung disease/immunodeficiencies, but without the right lung environment like this, it is almost NEVER seen!!
There is no universally accepted criteria, but the #ISHAM criteria is often used. Let's check it out!

Traditional obligatory criteria:
- Serum #IgE RAST >0.35 OR Allergic Skin Testing (+) to A. fumigatus
- Total Serum IgE >1000 Image
Read 6 tweets
#Azithromycin associated w/ #COVID_19 associated pulmonary #aspergillosis. OR 3.1 (1.1-8.5). Just published in @CMIJournal (bit.ly/2JN1fDS). Could it be a risk factor ? More on this hypothesis ⬇️ 1/5
#Azithromycin >1500mg in humans = inhibition of oxydative burst in #neutrophils up to 28 days after last dose. By Culic et al. (bit.ly/3mPkYkd) 2/5
#Neutrophils = first barrier against fungal infection. Oxydative burst necessary for NETs formation. Genetic defect in oxydative burst leads to CGD with well-known increased susceptibility to #aspergillosis (bit.ly/2VJu1aN). 3/5
Read 5 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!